BioLight Life Sciences Ltd (BOLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioLight Life Sciences Ltd (BOLT) has a cash flow conversion efficiency ratio of -0.137x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-5.49 Million ≈ $-14.72K USD) by net assets (ILA40.17 Million ≈ $107.70K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BioLight Life Sciences Ltd balance sheet quality to measure how much of total assets are equity-financed.
BioLight Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how BioLight Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of BioLight Life Sciences Ltd to evaluate the quality of earnings relative to operating cash generation.
BioLight Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioLight Life Sciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Soc Franc Casinos
PA:SFCA
|
0.092x |
|
Locate Technologies Ltd
AU:LOC
|
-0.104x |
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
0.736x |
|
Crown Point Energy Inc
V:CWV
|
-0.370x |
|
Toyo Ventures Holdings Bhd
KLSE:7173
|
0.099x |
|
Celyad SA
BR:CYAD
|
0.919x |
|
BAIYU Holdings Inc.
NASDAQ:BYU
|
-0.009x |
|
Green Technology Metals Ltd
AU:GT1
|
-0.017x |
Annual Cash Flow Conversion Efficiency for BioLight Life Sciences Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of BioLight Life Sciences Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see BOLT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ILA40.17 Million ≈ $107.70K |
ILA-10.85 Million ≈ $-29.10K |
-0.270x | +24.45% |
| 2024-12-31 | ILA30.74 Million ≈ $82.42K |
ILA-10.99 Million ≈ $-29.47K |
-0.358x | -13.15% |
| 2023-12-31 | ILA30.30 Million ≈ $81.24K |
ILA-9.58 Million ≈ $-25.68K |
-0.316x | -77.88% |
| 2022-12-31 | ILA53.69 Million ≈ $143.95K |
ILA-9.54 Million ≈ $-25.58K |
-0.178x | -8.84% |
| 2021-12-31 | ILA61.42 Million ≈ $164.66K |
ILA-10.03 Million ≈ $-26.88K |
-0.163x | +13.89% |
| 2020-12-31 | ILA60.11 Million ≈ $161.14K |
ILA-11.39 Million ≈ $-30.55K |
-0.190x | +15.87% |
| 2019-12-31 | ILA68.15 Million ≈ $182.70K |
ILA-15.36 Million ≈ $-41.17K |
-0.225x | +21.70% |
| 2018-12-31 | ILA77.80 Million ≈ $208.57K |
ILA-22.39 Million ≈ $-60.03K |
-0.288x | +90.87% |
| 2017-12-31 | ILA8.03 Million ≈ $21.53K |
ILA-25.32 Million ≈ $-67.88K |
-3.153x | -92.02% |
| 2016-12-31 | ILA16.41 Million ≈ $43.99K |
ILA-26.94 Million ≈ $-72.23K |
-1.642x | -221.44% |
| 2015-12-31 | ILA47.06 Million ≈ $126.17K |
ILA-24.04 Million ≈ $-64.44K |
-0.511x | +51.29% |
| 2014-12-31 | ILA25.74 Million ≈ $69.00K |
ILA-26.99 Million ≈ $-72.35K |
-1.049x | +11.60% |
| 2013-12-31 | ILA22.11 Million ≈ $59.27K |
ILA-26.23 Million ≈ $-70.31K |
-1.186x | -127.59% |
| 2012-12-31 | ILA37.34 Million ≈ $100.10K |
ILA-19.46 Million ≈ $-52.17K |
-0.521x | -- |
About BioLight Life Sciences Ltd
BioLight Life Sciences Ltd. engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel. The company offers TeaRx, a diagnostic platform intended for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid; TeaRx D… Read more